The most common genetic alteration in the SHOX2 gene were amplifications in the lung squamous cell carcinoma (LUSC) (20.53%), esophageal carcinoma (ESCA) (14.84%), cervical squamous cell carcinoma (CESC) (9.76%), head and neck cancer (HNSC) (8.99%) and ovarian serous cystadenocarcinoma (OV) (8.73%); mutations (2.65%) in the uterine corpus endometrial carcinoma (UCEC); and deep deletions (1.15%) in the Mesothelioma (MESO) (Fig. 5A). This evidence concerns the gene SHOX2 and cervical squamous cell carcinoma.